Verona Pharma

Read more
David Zaccardelli's photo - President & CEO of Verona Pharma

President & CEO

David Zaccardelli

CEO Approval Rating

86/100

Founded:

2005

Status:

PublicIndependent CompanyLondon Stock ExchangeVRP

VERONA PHARMA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

ReViral is the biggest rival of Verona Pharma. ReViral was founded in 2011, and its headquarters is in Hertfordshire, England. ReViral operates in the Pharmaceuticals industry. ReViral has 15 more employees than Verona Pharma.

Synairgen has been one of Verona Pharma's top competitors. Synairgen is a Public company that was founded in Southampton, England in 2003. Synairgen is in the Pharmaceuticals industry. Synairgen has 11 fewer employees vs. Verona Pharma.

Enterprise Therapeutics is Verona Pharma's #3 rival. Enterprise Therapeutics was founded in 2014 in Brighton, England. Enterprise Therapeutics is in the Pharmaceuticals field. Enterprise Therapeutics generates $7M more revenue than Verona Pharma.

Verona Pharma Quarterly and Annual Revenue

Coming soon for Verona Pharma!

Annual Revenue

Verona Pharma Acquisitions

No recent acquisitions found related to Verona Pharma

Verona Pharma Funding History

Since Verona Pharma was founded in 2005, it has participated in 4 rounds of funding. In total Verona Pharma has raised $348.5M. Verona Pharma's last funding round was on Nov 2020 for a total of $5.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Nov 2020
$5M

Silicon Valley Bank

Private Placement
Jul 2020
$200M
IPO
Apr 2017
$77.9M
-
Equity
Jun 2016
$65.6M

Since Verona Pharma was founded in 2005, it has participated in 4 rounds of funding. In total Verona Pharma has raised $348.5M. Verona Pharma's last funding round was on Nov 2020 for a total of $5.0M

Verona Pharma Investments

No recent investments found related to Verona Pharma

Verona Pharma News

June 10, 2021Biospectrum Asia

UK Pharma firms invest $219M to scale up a respiratory drug in China, Taiwan, HK, Macau

Verona Pharma and Nuance Pharma enters strategic collaboration to develop Ensifentrine by leveraging ... See more »
June 10, 2021MarketScreener

VRNA Investor Presentation June 2021

(marketscreener.com) Developing innovative therapies for the treatment of respiratory diseases June 2... See more »
May 25, 2021Markets Insider

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona ... See more »
May 4, 2021MarketScreener

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

(marketscreener.com) LONDON and RALEIGH, N.C., May 04, 2021 -- Verona Pharma plc , a clinical-stage b... See more »
April 29, 2021BioSpace

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announ... See more »

Verona Pharma Press Releases

November 28, 2019StreetInsider

Standard form for notification of major holdings

LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings...... See more »
April 4, 2019centralcharts

Grant of Options and RSUs and PDMR Dealings

LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”... See more »
January 14, 2019streetinsider

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

LONDON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”... See more »
January 14, 2019streetinsider

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

LONDON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma... See more »
January 14, 2019Interactive Investor

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet ... See more »
January 14, 2019CentralCharts

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical compa... See more »
January 9, 2019CENTRALCHARTS

Verona Pharma Receives WHO Approval for "ensifentrine" as Recommended INN for RPL554

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical compa... See more »

Verona Pharma Videos

Social Media

Verona Pharma Headquarters

3 More London Riverside

London, EnglandSE1 2RE

44-203-283-4200

Driving Directions »

Trending Companies

Verona Pharma Summary

ABOUT

Overview

Verona Pharma is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of respiratory diseases. Verona Pharma was founded in 2005. Verona Pharma's headquarters is located in London, England, GB SE1 2RE. It h...

CEO

Verona Pharma's President & CEO, David Zaccardelli, currently has an approval rating of 86%. Verona Pharma's primary competitors are ReViral, Synairgen & Enterprise Therapeutics.

Frequently Asked Questions about Verona Pharma

  1. When was Verona Pharma founded?

    Verona Pharma was founded in 2005
  2. Who is Verona Pharma's CEO?

    Verona Pharma's CEO is David Zaccardelli
  3. How much revenue does Verona Pharma generate?

    Verona Pharma generates $ < 1M in revenue
  4. How much funding does Verona Pharma have?

    Verona Pharma has historically raised $348.5M in funding
  1. Where is Verona Pharma's headquarters?

    Verona Pharma's headquarters is in London England, GB
  2. How many employees does Verona Pharma have?

    Verona Pharma has 25 employees
  3. What sector does Verona Pharma operate in?

    Verona Pharma is in Pharmaceuticals, Biotechnology
  4. Who are Verona Pharma's competitors?

    Verona Pharma's top competitors are ReViral, Synairgen, Enterprise Therapeutics